Becton, Dickinson and Company

BDX

US0758871091

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 12:03:16 2024-04-24 pm EDT			5-day change	1st Jan Change
234.1 ^USD	-0.09%		+0.65%	-4.15%

Apr. 05	Becton Dickinson Releases New Image-Enabled Cell Sorters	MT
Apr. 05	Becton, Dickinson and Company Increases Access to Cutting-Edge Image-Enabled, Spectral Cell Sorters	CI

Becton, Dickinson and Company authorizes a Buyback Plan.

November 03, 2021

The Board of Directors of Becton, Dickinson and Company has authorized a buyback plan on November 4, 2021.

Latest news about Becton, Dickinson and Company

Becton Dickinson Releases New Image-Enabled Cell Sorters	Apr. 05	MT
Becton, Dickinson and Company Increases Access to Cutting-Edge Image-Enabled, Spectral Cell Sorters	Apr. 05	CI
AngioDynamics Settles Patent Dispute with Becton, Dickinson Affiliate	Apr. 01	MT
AngioDynamics Settles Multi-Year Patent Dispute with Becton Dickinson & Co	Apr. 01	DJ
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	Mar. 21	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Mar. 21	MT
Sector Update: Health Care	Mar. 21	MT
Becton, Dickinson Raising Domestic Production of Syringes	Mar. 21	MT
Transcript : Becton, Dickinson and Company Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:30 AM	Mar. 13
Becton, Dickinson and Co. Enrolls First Person in Trial of Stent to Treat Peripheral Arterial Disease	Mar. 04	MT
Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease	Mar. 04	CI
Transcript : Becton, Dickinson and Company Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 08:00 AM	Feb. 29
Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024	Feb. 27	CI
Becton, Dickinson Seeks M&A	Feb. 26	CI
Transcript : Becton, Dickinson and Company - Special Call	Feb. 26
Becton, Dickinson Collaborating With Camtech Health for at-Home Cervical Cancer Screening in Singapore	Feb. 21	MT
Barclays Adjusts Price Target on Becton Dickinson and Co. to $305 From $301, Maintains Overweight Rating	Feb. 05	MT
Tranche Update on Becton, Dickinson and Company's Equity Buyback Plan announced on November 4, 2021.	Feb. 01	CI
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	Feb. 01	MT
Transcript : Becton, Dickinson and Company, Q1 2024 Earnings Call, Feb 01, 2024	Feb. 01
Becton, Dickinson's Fiscal Q1 Adjusted Earnings Down, Revenue Up; 2024 Guidance Revised	Feb. 01	MT
Becton Dickinson Lifts 2024 Outlook After Sales Rise in 1Q	Feb. 01	DJ
(BDX) BD (BECTON DICKINSON AND COMPANY) Sees Fiscal Year 2024 EPS Range $12.82 - $13.06	Feb. 01	MT
Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Posts Q1 Revenue $4.71B, vs. Street Est of $4.73B	Feb. 01	MT
Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Posts Q1 EPS $2.68, vs. Street Est of $2.40	Feb. 01	MT

Chart Becton, Dickinson and Company

Duration

Period

More charts

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-02 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Becton, Dickinson and Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

234.4 USD

Average target price

281.2 USD

Spread / Average Target

+20.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BECTON, DICKINSON AND COMPANY	-4.15%	67.71B
ABBOTT LABORATORIES	-3.21%	187B
MEDTRONIC PLC	-2.48%	108B
DEXCOM, INC.	+10.52%	53.07B
CENCORA, INC.	+15.68%	47.36B
HOYA CORPORATION	+6.01%	39.73B
WEST PHARMACEUTICAL SERVICES, INC.	+10.41%	28.56B
METTLER-TOLEDO INTERNATIONAL, INC.	+1.23%	26.55B
TERUMO CORPORATION	+15.97%	25.13B
ZIMMER BIOMET HOLDINGS, INC.	+0.19%	24.97B

Other Medical Equipment, Supplies & Distribution